US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
SG43179A1
(en)
|
1991-12-18 |
1997-10-17 |
Warner Lambert Co |
A process for the prepatation of a solid dispersion
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
ES2145063T3
(es)
*
|
1992-10-14 |
2000-07-01 |
Nippon Shinyaku Co Ltd |
Procedimiento de dislocacion del estado cristalino.
|
US5811547A
(en)
*
|
1992-10-14 |
1998-09-22 |
Nippon Shinyaju Co., Ltd. |
Method for inducing crystalline state transition in medicinal substance
|
DE69332291T2
(de)
*
|
1992-10-16 |
2003-07-31 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung von wachsmatrizes
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP0717988B1
(de)
*
|
1993-08-20 |
2001-10-17 |
Nippon Shinyaku Company, Limited |
Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
|
GB2281697A
(en)
*
|
1993-09-14 |
1995-03-15 |
Euro Celtique Sa |
Laxative compositions in capsules
|
DE69432186T2
(de)
*
|
1993-11-18 |
2004-05-06 |
Nippon Shinyaku Co., Ltd. |
Verfahren zur herstellung stabiler arzneimittel
|
DE19509807A1
(de)
*
|
1995-03-21 |
1996-09-26 |
Basf Ag |
Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
ATE251896T1
(de)
*
|
1994-12-19 |
2003-11-15 |
Daiichi Seiyaku Co |
Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
|
FR2736550B1
(fr)
*
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
ES2199289T3
(es)
*
|
1995-07-26 |
2004-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Dispersion solida de derivados de xantina.
|
TW487582B
(en)
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
HU227745B1
(en)
*
|
1996-05-20 |
2012-02-28 |
Janssen Pharmaceutica Nv |
Antifungal compositions containing itraconazole
|
US6139872A
(en)
*
|
1996-08-14 |
2000-10-31 |
Henkel Corporation |
Method of producing a vitamin product
|
JPH10114682A
(ja)
*
|
1996-10-11 |
1998-05-06 |
Shimizu Kagaku Kk |
グルコマンナン配合持効性内服用薬剤
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
EP1741424B1
(de)
|
1997-08-11 |
2018-10-03 |
Pfizer Products Inc. |
Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
|
PT901786E
(pt)
|
1997-08-11 |
2007-08-07 |
Pfizer Prod Inc |
Disperções farmacêuticas sólidas com biodisponibilidade melhorada
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
US6013280A
(en)
*
|
1997-10-07 |
2000-01-11 |
Fuisz Technologies Ltd. |
Immediate release dosage forms containing microspheres
|
WO1999034780A1
(de)
*
|
1998-01-12 |
1999-07-15 |
Bühler AG |
Verfahren und vorrichtung zum verkapseln von wirkstoffen
|
IE980115A1
(en)
*
|
1998-02-16 |
2000-02-09 |
Biovail Internat Ltd |
Solubilizing delivery systems and method of manufacture
|
BR9911072A
(pt)
*
|
1998-05-27 |
2001-02-06 |
Euro Celtique Sa |
Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
|
DE19842914A1
(de)
*
|
1998-09-18 |
2000-03-23 |
Basf Ag |
Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
|
DE19842753A1
(de)
|
1998-09-18 |
2000-03-23 |
Bayer Ag |
Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
|
US6350786B1
(en)
†
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US6455526B1
(en)
|
1998-12-16 |
2002-09-24 |
Aventis Pharmaceuticals, Inc. |
Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
|
SK285812B6
(sk)
*
|
1998-12-16 |
2007-08-02 |
Aventis Pharmaceuticals Inc. |
Farmaceutická kompozícia obsahujúca antagonistu serotonínového receptora a spôsob jej výroby
|
DE60039377D1
(de)
|
1999-02-09 |
2008-08-21 |
Pfizer Prod Inc |
Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
|
EP1027886B1
(de)
*
|
1999-02-10 |
2008-07-09 |
Pfizer Products Inc. |
Pharmazeutische feste Dispersionen
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
JP2000281561A
(ja)
*
|
1999-03-26 |
2000-10-10 |
Ajinomoto Co Inc |
新規溶媒法固体分散体製剤
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
MXPA01012170A
(es)
|
1999-05-27 |
2002-06-21 |
Euro Celtique Sa |
Preparacion para la aplicacion de agentes anti-infecciosos y/o anti-inflamatorios para partes externas o internas del cuerpo humano o animal en la remodelacion funcional y cosmetica y tratamientos de reparacion de tejidos.
|
US7300667B1
(en)
|
1999-05-27 |
2007-11-27 |
Euro-Celtique, S.A. |
Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
|
US7297344B1
(en)
|
1999-05-27 |
2007-11-20 |
Euro-Celtique, S.A. |
Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
DE19949897A1
(de)
*
|
1999-10-15 |
2001-04-19 |
Rainer Rogasch |
Formkörper und Verfahren zu dessen Herstellung
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
KR101216270B1
(ko)
|
1999-10-29 |
2012-12-31 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
DE60028754T2
(de)
|
1999-11-12 |
2007-05-31 |
Abbott Laboratories, Abbott Park |
Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
HUP0204372A3
(en)
|
1999-12-23 |
2004-06-28 |
Pfizer Prod Inc |
Pharmaceutical compositions providing enhanced drug concentrations
|
RU2277416C2
(ru)
*
|
2000-03-21 |
2006-06-10 |
Ниппон Синяку Ко., Лтд. |
Препараты для перорального введения с замедленным высвобождением
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
DE10031044A1
(de)
|
2000-06-26 |
2002-01-03 |
Bayer Ag |
Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
|
AU2001271055B2
(en)
*
|
2000-07-17 |
2005-07-07 |
Astellas Pharma Inc. |
Pharmaceutical composition improved in peroral absorbability
|
US7115279B2
(en)
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
DE60143704D1
(de)
*
|
2000-09-25 |
2011-02-03 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung einer medizinischen festen dispersion
|
CA2427815C
(en)
|
2000-10-30 |
2007-07-10 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
ITMI20010141A1
(it)
*
|
2001-01-26 |
2002-07-26 |
Giuliani Spa |
Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
|
DE60206889T2
(de)
*
|
2001-02-27 |
2006-07-27 |
Astrazeneca Ab |
Pharmazeutische formulierung enthaltend bicalutamid
|
GB0104752D0
(en)
*
|
2001-02-27 |
2001-04-18 |
Astrazeneca Ab |
Pharmaceutical compositions
|
US6465014B1
(en)
*
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
AU2002304387A1
(en)
|
2001-06-22 |
2003-01-08 |
Pfizer Products Inc. |
Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
|
ATE480226T1
(de)
*
|
2001-06-22 |
2010-09-15 |
Bend Res Inc |
Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
|
EP1269994A3
(de)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
EP1401399A2
(de)
*
|
2001-06-22 |
2004-03-31 |
Pfizer Products Inc. |
Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
|
EP1404300B1
(de)
*
|
2001-06-22 |
2009-09-30 |
Pfizer Products Inc. |
Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
SE0103424D0
(sv)
*
|
2001-10-15 |
2001-10-15 |
Astrazeneca Ab |
Pharmaceutical formulation
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
CA2473991C
(en)
*
|
2002-02-01 |
2009-09-15 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
EP1920766B1
(de)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
CN1309370C
(zh)
*
|
2002-02-01 |
2007-04-11 |
辉瑞产品公司 |
使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
|
US20030204180A1
(en)
*
|
2002-04-30 |
2003-10-30 |
Kimberly-Clark Worldwide, Inc. |
Temperature responsive delivery systems
|
ATE442130T1
(de)
|
2002-08-12 |
2009-09-15 |
Bend Res Inc |
Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
|
BR0317521A
(pt)
|
2002-12-20 |
2005-11-16 |
Pfizer Prod Inc |
Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
|
WO2004069180A2
(en)
*
|
2003-01-31 |
2004-08-19 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
US8486447B2
(en)
*
|
2003-02-03 |
2013-07-16 |
Novartis Ag |
Pharmaceutical formulation
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
BRPI0416596A
(pt)
*
|
2003-11-14 |
2007-01-30 |
Pfizer Prod Inc |
dispersões amorfas sólidas de um inibidor da mtp para tratamento da obesidade
|
BRPI0417492A
(pt)
*
|
2003-12-09 |
2007-05-29 |
Pfizer |
composições compreendendo um inibidor de protease de hiv
|
BRPI0507462A
(pt)
|
2004-02-04 |
2007-07-10 |
Pfizer Prod Inc |
compostos de quinolina substituìdos
|
US20050238721A1
(en)
*
|
2004-04-07 |
2005-10-27 |
Acquarulo Lawrence A Jr |
One step compounding extrusion of drug filled polymers
|
US20070237823A1
(en)
*
|
2004-05-04 |
2007-10-11 |
Thomas Bock |
Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
|
AP2006003768A0
(en)
|
2004-05-25 |
2006-10-31 |
Pfizer Prod Inc |
TetraazabenzoÄeÜazulene derivatives and analogs tehereof
|
DE602005010074D1
(de)
*
|
2004-05-28 |
2008-11-13 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
CA2605214C
(en)
|
2004-12-31 |
2016-07-12 |
Reddy Us Therapeutics, Inc. |
Benzylamine derivatives as cetp inhibitors
|
US8617604B2
(en)
|
2005-02-03 |
2013-12-31 |
Bend Research, Inc. |
Pharmaceutical compositions with enhanced performance
|
EP1690528A1
(de)
*
|
2005-02-11 |
2006-08-16 |
Abbott GmbH & Co. KG |
Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
|
US20080213339A1
(en)
*
|
2005-08-02 |
2008-09-04 |
Roger Imboden |
Pharmaceutical Composition Containing Indometacin and/or Acemetacin
|
US8187639B2
(en)
*
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
EP1933852B1
(de)
|
2005-09-27 |
2018-12-19 |
TissueTech, Inc. |
Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
|
WO2007062266A2
(en)
|
2005-11-28 |
2007-05-31 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
EP1832281A1
(de)
*
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes
|
EP2056818B1
(de)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Zusammensetzungen und verfahren für nervenschutz
|
MX347525B
(es)
|
2006-09-22 |
2017-04-27 |
Pharmacyclics Llc |
Inhibidores de tirosina cinasa de bruton.
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US7607596B1
(en)
|
2007-03-07 |
2009-10-27 |
Exxpharma, LLC |
Process for enhancing the solubility of poorly soluble drugs
|
US8309129B2
(en)
|
2007-05-03 |
2012-11-13 |
Bend Research, Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
US8703204B2
(en)
|
2007-05-03 |
2014-04-22 |
Bend Research, Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
|
US9545384B2
(en)
|
2007-06-04 |
2017-01-17 |
Bend Research, Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
|
EP2162120B1
(de)
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
|
NZ582772A
(en)
|
2007-07-17 |
2012-06-29 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CN101754962B
(zh)
*
|
2007-07-19 |
2013-12-25 |
赛马拜制药公司 |
作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
|
WO2009026461A2
(en)
*
|
2007-08-21 |
2009-02-26 |
Board Of Regents, The University Of Texas System |
Thermo-kinetic mixing for pharmaceutical applications
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
WO2009038112A1
(ja)
*
|
2007-09-21 |
2009-03-26 |
Shionogi & Co., Ltd. |
Npyy5受容体拮抗剤を含有する固形製剤
|
AU2008303129B2
(en)
*
|
2007-09-25 |
2013-08-01 |
Formulex Pharma Innovations Ltd. |
Compositions comprising lipophilic active compounds and method for their preparation
|
WO2009053635A1
(fr)
*
|
2007-10-11 |
2009-04-30 |
L'oreal |
Composition cosmetique structuree
|
FR2922100B1
(fr)
*
|
2007-10-11 |
2009-12-11 |
Oreal |
Procede de preparation de particules semi-solides a interet cosmetique
|
EP2231169B1
(de)
|
2007-12-06 |
2016-05-04 |
Bend Research, Inc. |
Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
|
US9233078B2
(en)
|
2007-12-06 |
2016-01-12 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
US20100048914A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
JP5711655B2
(ja)
*
|
2008-03-31 |
2015-05-07 |
シマベイ セラピューティクス, インコーポレーテッド |
オキシメチレンアリール化合物およびその使用
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
EP3023433A1
(de)
|
2009-02-05 |
2016-05-25 |
Tokai Pharmaceuticals, Inc. |
Neuartige prodrugs von steroidalen cyp17-hemmern/-antiandrogenen
|
TWI404719B
(zh)
|
2009-04-03 |
2013-08-11 |
Hoffmann La Roche |
組合物及其用途
|
US9175066B2
(en)
|
2009-04-24 |
2015-11-03 |
Tissuetech, Inc. |
Compositions containing HC-HA complex and methods of use thereof
|
WO2010147978A1
(en)
|
2009-06-16 |
2010-12-23 |
Pfizer Inc. |
Dosage forms of apixaban
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
EP2483281B1
(de)
*
|
2009-10-01 |
2014-06-04 |
Cymabay Therapeutics, Inc. |
Substituierte tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidinsalze
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
CN106220623A
(zh)
|
2009-11-06 |
2016-12-14 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
JP5749790B2
(ja)
*
|
2010-03-26 |
2015-07-15 |
ダウ グローバル テクノロジーズ エルエルシー |
多層溶融押出フィルム
|
CN103153580A
(zh)
*
|
2010-03-26 |
2013-06-12 |
陶氏环球技术有限责任公司 |
制备熔体挤出的膜的方法和熔体挤出的膜
|
US20110236465A1
(en)
*
|
2010-03-26 |
2011-09-29 |
Hall Mark J |
Melt-extruded film
|
US20130030237A1
(en)
|
2010-04-15 |
2013-01-31 |
Charles Theuer |
Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
|
EP2563759B1
(de)
|
2010-04-27 |
2022-04-06 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
AU2011261185A1
(en)
|
2010-06-03 |
2013-01-10 |
Pharmacyclics, Inc. |
The use of inhibitors of Bruton's tyrosine kinase (Btk)
|
CN103037843A
(zh)
*
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
AU2011272839B2
(en)
|
2010-07-02 |
2015-04-02 |
The Procter & Gamble Company |
Methods of delivering a health care active by administering personal health care articles comprising a filament
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2012109075A1
(en)
|
2011-02-07 |
2012-08-16 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
MX2013008476A
(es)
|
2011-02-17 |
2013-08-12 |
Hoffmann La Roche |
Proceso para cristalizacion controlada de un ingrediente farmaceutico activo a partir del estado liquido superenfriado por extrusion de fusion en caliente.
|
AR085279A1
(es)
|
2011-02-21 |
2013-09-18 |
Plexxikon Inc |
Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
|
DE102011015370A1
(de)
*
|
2011-03-29 |
2012-10-04 |
Emodys Gmbh |
Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
EP2717888B1
(de)
|
2011-06-10 |
2020-09-09 |
Tissuetech, Inc. |
Verfahren zur verarbeitung fötaler gewebesubstrate
|
KR101774223B1
(ko)
|
2011-08-18 |
2017-09-12 |
닥터 레디스 레보러터리즈 리미티드 |
콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
|
ES2627820T3
(es)
|
2011-09-13 |
2017-07-31 |
Pharmacyclics, Inc. |
Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
|
IN2014CN02290A
(de)
|
2011-09-27 |
2015-06-19 |
Reddys Lab Ltd Dr |
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
JP2015508407A
(ja)
|
2012-01-06 |
2015-03-19 |
アビデ セラピューティクス,インク. |
カルバメート化合物およびその製造および使用
|
IN2012DE00674A
(de)
|
2012-03-07 |
2015-08-21 |
Nat Inst Of Pharmaceutical Education And Res Niper |
|
EP2834238B1
(de)
|
2012-04-06 |
2017-02-01 |
Pfizer Inc. |
Diacylglycerol-acyltransferase-2-hemmer
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
UA126959C2
(uk)
|
2012-06-04 |
2023-03-01 |
Фармасайклікс Ллс |
Фармацевтична композиція, що містить інгібітор тирозинкінази брутона
|
EP3838293A1
(de)
|
2012-07-11 |
2021-06-23 |
Tissuetech, Inc. |
Zusammensetzungen mit hc-ha/ptx3-komplexen und verfahren zur verwendung davon
|
WO2014052914A1
(en)
|
2012-09-28 |
2014-04-03 |
University Of Washington Through Its Center For Commercialization |
Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR102191562B1
(ko)
*
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
JP2016503420A
(ja)
|
2012-11-19 |
2016-02-04 |
ドクター レディズ ラボラトリーズ リミテッド |
Cetp阻害剤の薬学的組成物
|
JP6150518B2
(ja)
|
2012-12-27 |
2017-06-21 |
花王株式会社 |
ポリフェノール組成物の製造方法
|
WO2014128564A2
(en)
|
2013-02-21 |
2014-08-28 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions of cetp inhibitors
|
EP4066841A1
(de)
|
2013-03-14 |
2022-10-05 |
University of Maryland, Baltimore |
Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
|
EP2837391B1
(de)
|
2013-08-12 |
2017-05-10 |
Shin-Etsu Chemical Co., Ltd. |
Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
|
CA2920317A1
(en)
|
2013-08-12 |
2015-02-19 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
US9296882B2
(en)
|
2013-09-04 |
2016-03-29 |
Zzyzx Polymers LLC |
Methods for increasing throughput rates of solid-state extrusion devices
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20150104508A1
(en)
*
|
2013-10-12 |
2015-04-16 |
Zzyzx Polymers LLC |
Devices, compositions, and methods for fabricating drug delivery systems
|
EP3077388A1
(de)
|
2013-12-05 |
2016-10-12 |
Pharmacyclics, LLC |
Hemmer der bruton-tyrosinkinase
|
WO2015120389A1
(en)
|
2014-02-10 |
2015-08-13 |
Patara Pharma, LLC |
Mast cell stabilizers treatment for systemic disorders
|
CN106535889A
(zh)
|
2014-02-10 |
2017-03-22 |
帕塔拉制药有限责任公司 |
用于治疗肺疾病的肥大细胞稳定剂
|
SG11201606779RA
(en)
|
2014-03-17 |
2016-10-28 |
Pfizer |
Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
|
US10231929B2
(en)
|
2014-03-18 |
2019-03-19 |
Takeda Pharmaceutical Company Limited |
Solid dispersion
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US10894058B2
(en)
|
2014-08-29 |
2021-01-19 |
Kao Corporation |
Method for producing solid dispersion containing hardly soluble polyphenol
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
CA2964068A1
(en)
*
|
2014-09-19 |
2016-03-24 |
Board Of Regents, The University Of Texas System |
Methods of preparing extrudates
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
EP3253766B1
(de)
|
2015-02-06 |
2019-09-04 |
University of Washington |
Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
AU2016225000B2
(en)
|
2015-02-27 |
2021-04-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
MA41643A
(fr)
|
2015-03-03 |
2018-01-09 |
Pharmacyclics Llc |
Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
SG10202012002TA
(en)
|
2015-05-11 |
2021-01-28 |
Lundbeck La Jolla Research Center Inc |
Methods of treating inflammation or neuropathic pain
|
TWI720984B
(zh)
|
2015-05-20 |
2021-03-11 |
美商帝聖工業公司 |
用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
|
CN117547528A
(zh)
|
2015-05-28 |
2024-02-13 |
瑞迪博士实验室有限公司 |
用于治疗疼痛的塞来昔布口服组合物
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
EP3331522A1
(de)
|
2015-08-07 |
2018-06-13 |
Patara Pharma LLC |
Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
EP3340982B1
(de)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Verbindungen zur behandlung von immun- und entzündungserkrankungen
|
JP2018525411A
(ja)
|
2015-08-31 |
2018-09-06 |
ファーマサイクリックス エルエルシー |
多発性骨髄腫を治療するためのbtk阻害剤の組み合わせ
|
AU2016374497B2
(en)
|
2015-12-16 |
2022-03-10 |
The Walter And Eliza Hall Institute Of Medical Research |
Inhibition of cytokine-induced SH2 protein in NK cells
|
BR112018014590A2
(pt)
|
2016-01-19 |
2018-12-11 |
Janssen Pharmaceutica Nv |
formulações/composições compreendendo um inibidor de btk
|
AU2017208473B2
(en)
|
2016-01-19 |
2022-04-21 |
Janssen Pharmaceutica Nv |
Formulations/compositions comprising a BTK inhibitor
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
AU2017246334C1
(en)
|
2016-04-04 |
2022-11-17 |
Sinopia Biosciences, Inc. |
Treating extrapyramidal syndrome using Trapidil
|
AU2017263574B2
(en)
|
2016-05-12 |
2022-11-17 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
US11045550B2
(en)
|
2016-05-13 |
2021-06-29 |
Merck Patent Gmbh |
Use of an amino sugar as plasticizer
|
KR20230151062A
(ko)
|
2016-05-13 |
2023-10-31 |
메르크 파텐트 게엠베하 |
용융 압출 적용을 위한 중합체의 입자 크기 및 분포
|
CA3025268A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
EP3448389B1
(de)
|
2016-06-27 |
2021-09-29 |
Achillion Pharmaceuticals, Inc. |
Chinazolin- und indolderivate zur behandlung von medizinischen störungen
|
CA3030821A1
(en)
|
2016-07-18 |
2018-01-25 |
Arthrosi Therapeutics, Inc. |
Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
|
CN109862896A
(zh)
|
2016-08-03 |
2019-06-07 |
西玛贝医药公司 |
用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
CN109843868A
(zh)
|
2016-08-26 |
2019-06-04 |
科泰纳制药公司 |
Olig2活性的抑制
|
EP3506893A4
(de)
|
2016-08-31 |
2020-01-22 |
Respivant Sciences GmbH |
Cromolynzusammensetzungen zur behandlung von chronischem husten aufgrund von idiopathischer pulmonaler fibrose
|
EP3522983A4
(de)
|
2016-10-07 |
2020-06-03 |
Respivant Sciences GmbH |
Cromolynzusammensetzung zur behandlung von lungenfibrose
|
EP3534881A1
(de)
|
2016-11-07 |
2019-09-11 |
Merck Patent GmbH |
Tablette mit kontrollierter freisetzung auf basis von polyvinylalkohol und deren herstellung
|
CA3042770A1
(en)
|
2016-11-07 |
2018-05-11 |
Merck Patent Gmbh |
Anti-alcohol-induced dose dumping tablet based on polyvinyl alcohol
|
WO2018083113A1
(en)
|
2016-11-07 |
2018-05-11 |
Merck Patent Gmbh |
Instant release capsule based on hot melt extruded polyvinyl alcohol
|
BR112019009992A2
(pt)
|
2016-11-16 |
2019-08-27 |
Abide Therapeutics Inc |
formulações farmacêuticas
|
RS65016B1
(sr)
|
2016-11-16 |
2024-01-31 |
H Lundbeck As |
Kristalni oblik magl inhibitora
|
CA3056030A1
(en)
|
2017-03-10 |
2018-09-13 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
CN115093337A
(zh)
*
|
2017-08-01 |
2022-09-23 |
浙江普利药业有限公司 |
一种马来酸曲美布汀晶型及其制备方法
|
US11779573B2
(en)
|
2017-09-01 |
2023-10-10 |
University Of Washington |
Crystalline forms of compounds for preventing or treating sensory hair cell death
|
WO2019094434A1
(en)
|
2017-11-07 |
2019-05-16 |
The Regents Of The University Of Michigan |
Therapeutic combination for treatment of cerebellar ataxia
|
CA3082077A1
(en)
|
2017-11-10 |
2019-05-16 |
The Regents Of The University Of Michigan |
Ash1l degraders and methods of treatment therewith
|
CA3084809A1
(en)
|
2017-12-07 |
2019-06-13 |
The Regents Of The University Of Michigan |
Nsd family inhibitors and methods of treatment therewith
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
CN112533581A
(zh)
|
2018-06-07 |
2021-03-19 |
密歇根大学董事会 |
Prc1抑制剂及用其进行治疗的方法
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
US20200069742A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
MX2021002428A
(es)
|
2018-08-31 |
2023-01-02 |
Pfizer |
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
EP3866773A4
(de)
|
2018-10-16 |
2022-10-26 |
Georgia State University Research Foundation, Inc. |
Kohlenmonoxid-prodrugs zur behandlung von erkrankungen
|
US10925904B2
(en)
|
2018-11-06 |
2021-02-23 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
AU2019417833A1
(en)
|
2018-12-31 |
2021-06-24 |
Biomea Fusion, Inc. |
Irreversible inhibitors of menin-MLL interaction
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
WO2020190890A1
(en)
|
2019-03-15 |
2020-09-24 |
Unicycive Therapeutics Inc. |
Nicorandil derivatives
|
WO2020210205A1
(en)
*
|
2019-04-08 |
2020-10-15 |
Cosci Med-Tech Co., Ltd |
Methods of improving pharmaceutical substance solubilization and products thereof
|
CA3136880C
(en)
|
2019-04-19 |
2023-09-19 |
Pfizer Inc. |
Anti-proliferative agents for treating pah
|
CN113874019A
(zh)
|
2019-05-20 |
2021-12-31 |
辉瑞大药厂 |
用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
|
EP3990452A1
(de)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazolderivate als bckdk-inhibitoren zur behandlung verschiedener erkrankungen
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
US11702393B2
(en)
|
2020-04-21 |
2023-07-18 |
H. Lundbeck A/S |
Synthesis of a monoacylglycerol lipase inhibitor
|
AU2021289169B2
(en)
|
2020-06-09 |
2024-01-04 |
Pfizer Inc. |
Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
|
US11858925B2
(en)
|
2020-07-10 |
2024-01-02 |
The Regents Of The University Of Michigan |
GAS41 inhibitors and methods of use thereof
|
EP4263542A1
(de)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
WO2022238507A1
(en)
|
2021-05-11 |
2022-11-17 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
US20230120115A1
(en)
|
2021-08-11 |
2023-04-20 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
CA3229150A1
(en)
|
2021-08-20 |
2023-02-23 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
TW202337429A
(zh)
|
2021-12-01 |
2023-10-01 |
美商輝瑞股份有限公司 |
支鏈酮酸脫氫酶激酶(bckdk)抑制劑及/或降解劑
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
TW202340177A
(zh)
|
2021-12-30 |
2023-10-16 |
美商拜歐米富士恩股份有限公司 |
作為 flt3抑制劑之吡嗪化合物
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|